Back to top
more

AngioDynamics (ANGO)

(Delayed Data from NSDQ)

$5.68 USD

5.68
248,652

+0.02 (0.35%)

Updated Jul 3, 2024 01:00 PM ET

After-Market: $5.66 -0.02 (-0.35%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (155 out of 249)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for ANGO

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for AngioDynamics, Inc falls in the month of May.

All items in Millions except Per Share data.

5/31/2024 5/31/2023 5/31/2022 5/31/2021 5/31/2020
Assets          
Cash & Equivalents -99,999 45 29 48 54
Receivables NA 53 52 35 31
Notes Receivable NA 0 0 0 0
Inventories NA 55 51 49 60
Other Current Assets NA 11 11 9 7
Total Current Assets NA 164 143 141 153
Net Property & Equipment NA 44 45 37 28
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 270 353 370 398
Deposits & Other Assets NA 54 11 13 15
Total Assets NA 533 553 561 594
Liabilities & Shareholders Equity 5/31/2024 5/31/2023 5/31/2022 5/31/2021 5/31/2020
Notes Payable NA 0 0 0 0
Accounts Payable NA 40 28 20 19
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 27 35 35 29
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 17 11 3 3
Total Current Liabilities NA 84 74 58 51
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 13 16 20 24
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 50 25 20 40
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 8 13 24 24
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 154 128 122 139
Shareholders Equity 5/31/2024 5/31/2023 5/31/2022 5/31/2021 5/31/2020
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 599 587 574 562
Retained Earnings NA -211 -158 -132 -100
Other Equity NA -5 1 3 -1
Treasury Stock NA 6 6 6 6
Total Shareholder's Equity NA 378 424 439 455
Total Liabilities & Shareholder's Equity NA 533 553 561 594
Total Common Equity 0 378 424 439 455
Shares Outstanding 40.00 39.20 38.70 38.10 37.60
Book Value Per Share 0.00 9.65 10.97 11.53 12.10

Fiscal Year End for AngioDynamics, Inc falls in the month of May.

All items in Millions except Per Share data.

5/31/2024 2/29/2024 11/30/2023 8/31/2023 5/31/2023
Assets          
Cash & Equivalents -99,999 78 61 58 45
Receivables NA 49 52 50 53
Notes Receivable NA 0 0 0 0
Inventories NA 58 64 60 55
Other Current Assets NA 11 9 8 11
Total Current Assets NA 197 185 175 164
Net Property & Equipment NA 37 43 43 44
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 82 263 266 270
Deposits & Other Assets NA 9 8 9 54
Total Assets NA 325 500 494 533
Liabilities & Shareholders Equity 5/31/2024 2/29/2024 11/30/2023 8/31/2023 5/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 35 38 25 40
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 31 29 26 27
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 20 11 7 17
Total Current Liabilities NA 86 78 57 84
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 6 18 1 13
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 0 0 0 50
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 3 7 8
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 106 98 66 154
Shareholders Equity 5/31/2024 2/29/2024 11/30/2023 8/31/2023 5/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 609 605 604 599
Retained Earnings NA -382 -194 -165 -211
Other Equity NA -3 -5 -6 -5
Treasury Stock NA 6 6 6 6
Total Shareholder's Equity NA 219 401 428 378
Total Liabilities & Shareholder's Equity NA 325 500 494 533
Total Common Equity 0 219 401 428 378
Shares Outstanding 40.00 39.80 39.80 39.80 39.20
Book Value Per Share 0.00 5.49 10.08 10.75 9.65